NEWS

Circassia Initiates Further Phase II Clinical Study Of Toleromune(R) Anti Allergy Technology

Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.

Self-Adjusted Dosing May Be The Best Treatment For Hay Fever

Hay fever, the often seasonal allergy that affects between 10 and 20 percent of the American population, is best controlled through a course of patient-adjusted dosing, according to new research published in the September 2008 edition of Otolaryngology - Head and Neck Surgery.

Society's Lack Of Food Allergies Impacts Those Afflicted With Food Allergies

The level of knowledge and understanding of children with food allergies varies significantly across three key groups: pediatricians and family physicians, the general public and families who have a child with food allergies. The article describing the new findings was published in the September issue of BioMed Central Pediatrics.

Pollution, Everyday Allergens, May Be Sources Of Laryngitis

Everyday exposure to environmental tobacco smoke, allergens, and air pollution may be the root of chronic cases of laryngitis, says new research presented at the 2008 American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO in Chicago, IL.

ImVisioN Therapeutics Starts Phase I Clinical Trial Of IVN201 Against Cat Dander Allergy And Raises CHF 4.6 M

ImVisioN Therapeutics AG., a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT™), announced that it has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for cat dander allergy. The Company also announced the closing of a Series A Financing round of CHF 4.6 M, allowing the clinical development of IVN201. The financing round was led by Aravis Venture Associates AG and involved the participation of the founding investor Nextech Venture and private individuals.

Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients.

Health Canada Reminds Parents Of School Lunch Allergen Safety

As children head back to the classroom, Health Canada is reminding parents of the importance of allergy awareness when packing lunches for their children. Severe allergic reactions can occur quickly and without warning, and some foods can be life-threatening to allergic children.

Key Allergy Gene Discovered By Munich Researchers

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment (ZAUM) of the Technische Universitat Munchen, scientists at the Helmholtz Zentrum Munchen have pinpointed a major gene for allergic diseases. The gene was localized using cutting edge technologies for examining the whole human genome at the Helmholtz Zentrum Munchen.